

August 28, 2015
Seikagaku Corporation
(Securities Code: TSE 4548)

Seikagaku Announces Termination of the License Agreement with Can-Fite BioPharma Ltd. for a Therapeutic Agent for Rheumatoid Arthritis

Seikagaku Corporation (Tokyo) today announces that it has agreed to terminate the license agreement with an Israeli bio-venture, Can-Fite BioPharma Ltd. (Petah-Tikva, Israel; "Can-Fite"), regarding a low-molecular chemical compound adenosine A3 receptor agonist (development code: CF101 and SI-615 for Can-Fite and Seikagaku, respectively). The termination is to become effective on August 27, 2015.

Seikagaku had acquired in Japan the right to develop, produce and market the compound indicated for inflammatory diseases (excluding ophthalmic diseases) in September 2006. Seikagaku designated rheumatoid arthritis as its high-priority target disease and conducted a Phase I clinical trial in Japan. However, as result of a comprehensive re-assessment of its product strategy for rheumatoid arthritis, Seikagaku has reached the conclusion that it will discontinue the development of the product and terminate the license agreement.

Seikagaku will continue to focus its research and development on glycoscience, and engage in efficient new drug development with GAGs (glycosaminoglycans) as target substances and orthopedic diseases, ophthalmic diseases, and immune and allergic diseases as target diseases.

#####